BMY logo

Bristol-Myers Squibb Company

BMY
Healthcare|Drug Manufacturers - General|US
$62.14
-0.99 (-1.57%)
DCF Value
$239.82
Graham Number
$34.15
Cash / Share
$6.16

Financials

Financial Snapshot

Market Cap
$127.02B
Enterprise Value
$162.26B
Revenue (TTM)
$50.03B
Net Income (TTM)
$9.24B
Cash & Investments
$12.58B
Net Cash
-$32.23B
Free Cash Flow (TTM)
$9.29B
Operating CF (TTM)
$10.65B
Debt/Equity
1.91

Cash Runway & Burn Rate

Company is cash-flow positive.

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Investments
$6.35B$6.81B$8.76B$15.39B$16.45B$17.22B$9.25B$12.28B$10.86B$10.67B$12.58B
Operating Cash Flow
$3.06B$5.28B$7.07B$8.21B$14.05B$16.21B$13.07B$13.86B$15.19B$14.16B$10.65B
Free Cash Flow
$1.84B$4.22B$6.12B$7.37B$13.30B$15.23B$11.95B$12.65B$13.94B$12.85B$9.29B
Capital Expenditure
-$1.22B-$1.05B-$951.0M-$836.0M-$753.0M-$973.0M-$1.12B-$1.21B-$1.25B-$1.31B-$1.37B
Financing Cash Flow
-$2.65B-$4.08B-$3.54B$7.62B-$1.15B-$16.22B-$16.96B-$9.42B$5.13B-$10.35B-$11.44B

R&D Spending

R&D (TTM)
$10.56B
R&D Intensity
21.1%
R&D Growth vs Prior
+6.1%
MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$19.43B$20.78B$22.56B$26.14B$42.52B$46.38B$46.16B$45.01B$48.30B$48.20B$50.03B
R&D Expense
$5.01B$6.47B$6.33B$6.15B$11.14B$10.20B$9.51B$9.30B$11.16B$9.95B$10.56B
R&D % of Revenue
25.8%31.1%28.1%23.5%26.2%22.0%20.6%20.7%23.1%20.6%21.1%
SG&A
$4.98B$4.75B$4.55B$4.87B$7.66B$7.69B$7.81B$7.77B$8.41B$7.27B$7.32B

Income Statement

MetricTrend2016201720182019202020212022202320242025TTM
Revenue
$19.43B$20.78B$22.56B$26.14B$42.52B$46.38B$46.16B$45.01B$48.30B$48.20B$50.03B
Cost of Revenue
$4.97B$6.01B$6.47B$8.08B$11.77B$9.94B$10.14B$10.69B$13.97B$13.94B$15.39B
Gross Profit
$14.46B$14.76B$16.09B$18.07B$30.75B$36.45B$36.02B$34.31B$34.33B$34.26B$34.64B
R&D
$5.01B$6.47B$6.33B$6.15B$11.14B$10.20B$9.51B$9.30B$11.16B$9.95B$10.56B
SG&A
$4.98B$4.75B$4.55B$4.87B$7.66B$7.69B$7.81B$7.77B$8.41B$7.27B$7.32B
Operating Income
$4.47B$3.45B$5.11B$5.91B$2.18B$8.54B$9.10B$8.20B$5.89B$13.72B$13.05B
Interest Expense
$167.0M$196.0M$183.0M$656.0M$1.42B$1.33B$1.23B$1.17B$1.95B$1.89B$1.65B
Pretax Income
$5.92B$5.13B$5.97B$4.97B-$6.87B$8.10B$7.71B$8.44B-$8.38B$9.33B$11.33B
Net Income
$4.46B$1.01B$4.92B$3.44B-$9.02B$6.99B$6.33B$8.03B-$8.95B$7.05B$9.24B
EPS (Diluted)
2.650.613.032.01-3.983.122.953.86-4.413.454.51
EBITDA
$6.46B$6.12B$6.79B$7.38B$4.93B$20.12B$19.22B$19.37B$3.17B$15.23B$15.15B
Shares Out. (M)
1680.001652.001637.001712.002258.002245.002146.002078.002027.002041.002053.00

Balance Sheet

MetricTrend2016201720182019202020212022202320242025TTM
Cash & Equivalents
$4.24B$5.42B$6.91B$12.35B$14.55B$13.98B$9.12B$11.46B$10.35B$10.21B$9.57B
Short-Term Investments
$2.11B$1.39B$1.85B$3.05B$1.90B$3.24B$130.0M$816.0M$513.0M$464.0M$3.01B
Total Current Assets
$13.70B$14.85B$17.72B$29.35B$30.19B$33.26B$27.27B$31.77B$29.78B$29.39B$29.77B
Total Assets
$33.71B$33.55B$34.99B$129.94B$118.48B$109.31B$96.82B$95.16B$92.60B$90.04B$88.77B
Total Current Liabilities
$8.84B$9.56B$10.65B$18.30B$19.08B$21.87B$21.89B$22.26B$23.77B$23.42B$18.75B
Long-Term Debt
$5.72B$6.97B$5.65B$43.39B$48.34B$39.60B$35.06B$36.65B$47.60B$42.85B$41.85B
Total Liabilities
$17.36B$21.70B$20.86B$78.25B$80.60B$73.31B$65.70B$65.67B$76.22B$71.53B$65.37B
Stockholders' Equity
$16.18B$11.74B$14.03B$51.60B$37.82B$35.95B$31.06B$29.43B$16.34B$18.47B$23.40B
Retained Earnings
$33.51B$31.16B$34.06B$34.47B$21.28B$23.82B$25.50B$28.77B$14.91B$16.90B$21.19B

Cash Flow Statement

MetricTrend2016201720182019202020212022202320242025TTM
Operating Cash Flow
$3.06B$5.28B$7.07B$8.21B$14.05B$16.21B$13.07B$13.86B$15.19B$14.16B$10.65B
Capital Expenditure
-$1.22B-$1.05B-$951.0M-$836.0M-$753.0M-$973.0M-$1.12B-$1.21B-$1.25B-$1.31B-$1.37B
Free Cash Flow
$1.84B$4.22B$6.12B$7.37B$13.30B$15.23B$11.95B$12.65B$13.94B$12.85B$9.29B
Investing Cash Flow
$1.48B-$66.0M-$2.00B-$9.91B-$10.86B-$538.0M-$1.06B-$2.29B-$21.35B-$4.13B-$5.31B
Financing Cash Flow
-$2.65B-$4.08B-$3.54B$7.62B-$1.15B-$16.22B-$16.96B-$9.42B$5.13B-$10.35B-$11.44B
Issuance of Stock
$181.0M$0.00$0.00$0.00$0.00$0.00$0.00$0.00-$106.0M-$128.0M-$26.0M
Repurchase of Stock
-$231.0M-$2.47B-$320.0M-$7.30B-$1.55B-$6.29B-$8.00B-$5.16B$0.00$0.00-$98.0M
Net Debt Issuance
$110.0M$991.0M-$548.0M$17.65B$3.93B-$6.18B-$5.31B$456.0M$10.10B-$5.17B-$6.26B
Stock Based Comp.
$205.0M$199.0M$221.0M$441.0M$779.0M$583.0M$457.0M$518.0M$507.0M$553.0M$552.0M
Net Change in Cash
$1.85B$1.18B$1.49B$5.91B$2.15B-$657.0M-$4.99B$2.19B-$1.17B-$137.0M-$6.15B

Dilution Tracker

Shares Outstanding
2044M
5-Year Share Growth
-9.6%
Stock Issuance (TTM)
-$26.0M
MetricTrend2016201720182019202020212022202320242025TTM
Shares Out. (M)
1680.001652.001637.001712.002258.002245.002146.002078.002027.002041.002053.00
Change vs Prior %
—-1.7%-0.9%4.6%31.9%-0.6%-4.4%-3.2%-2.5%0.7%0.6%
Stock Issuance
$181.0M$0.00$0.00$0.00$0.00$0.00$0.00$0.00-$106.0M-$128.0M-$26.0M
Stock Repurchase
-$231.0M-$2.47B-$320.0M-$7.30B-$1.55B-$6.29B-$8.00B-$5.16B$0.00$0.00-$98.0M
Stock Based Comp.
$205.0M$199.0M$221.0M$441.0M$779.0M$583.0M$457.0M$518.0M$507.0M$553.0M$552.0M

Margins & Profitability

MetricTrend2016201720182019202020212022202320242025TTM
Gross Margin %
74.4%71.1%71.3%69.1%72.3%78.6%78.0%76.2%71.1%71.1%69.2%
Operating Margin %
23.0%16.6%22.7%22.6%5.1%18.4%19.7%18.2%12.2%28.5%26.1%
Net Margin %
22.9%4.8%21.8%13.2%-21.2%15.1%13.7%17.8%-18.5%14.6%18.5%
EBITDA Margin %
33.3%29.4%30.1%28.2%11.6%43.4%41.6%43.0%6.6%31.6%30.3%
FCF Margin %
9.5%20.3%27.1%28.2%31.3%32.8%25.9%28.1%28.9%26.7%18.6%
ROE %
27.6%8.6%35.1%6.7%-23.8%19.5%20.4%27.3%-54.8%38.2%43.9%
ROA %
13.2%3.0%14.1%2.6%-7.6%6.4%6.5%8.4%-9.7%7.8%10.4%
ROIC %
13.2%2.6%16.3%3.6%2.1%8.0%9.4%10.2%8.3%15.0%14.9%
R&D / Revenue %
25.8%31.1%28.1%23.5%26.2%22.0%20.6%20.7%23.1%20.6%21.1%

Growth (Year over Year)

Fiscal years. Rising share count growth means dilution.

MetricTrend2016201720182019202020212022202320242025
Revenue
17.3%6.9%8.6%15.9%62.6%9.1%-0.5%-2.5%7.3%-0.2%
Gross Profit
14.3%2.1%9.0%12.3%70.2%18.5%-1.2%-4.7%0.1%-0.2%
Operating Income
158.2%-22.9%48.4%15.6%-63.2%292.1%6.6%-10.0%-28.2%133.1%
Net Income
184.8%-77.4%388.6%-30.1%-362.1%177.6%-9.5%26.8%-211.5%178.8%
EPS (Diluted)
173.2%-77.0%396.7%-33.7%-298.0%178.4%-5.4%30.8%-214.2%178.2%
Operating Cash Flow
45.3%72.5%34.0%16.2%71.2%15.3%-19.4%6.1%9.6%-6.8%
Free Cash Flow
43.4%129.0%44.9%20.6%80.3%14.5%-21.6%5.9%10.2%-7.9%
R&D Expense
-15.3%29.1%-2.1%-2.9%81.2%-8.5%-6.7%-2.2%20.0%-10.8%
SG&A Expense
-0.4%-4.6%-4.2%7.0%57.3%0.4%1.6%-0.5%8.3%-13.6%
Total Assets
6.2%-0.5%4.3%271.4%-8.8%-7.7%-11.4%-1.7%-2.7%-2.8%
Book Value / Share
13.1%-26.4%20.1%250.5%-44.7%-3.4%-9.9%-2.5%-43.3%12.1%
Debt
0.3%18.7%-7.7%546.9%8.7%-11.8%-10.7%1.8%23.5%-7.9%
Diluted Shares
0.1%-1.7%-0.9%4.6%31.9%-0.6%-4.4%-3.2%-2.5%0.7%

Valuation

P/E (TTM)13.75
10Y Low / Med / High13.22 / 21.89 / 100.46
P/S2.54
10Y Low / Med / High2.28 / 3.32 / 5.03
P/B5.42
10Y Low / Med / High2.12 / 5.96 / 8.59
EV/EBITDA10.71
10Y Low / Med / High7.03 / 15.49 / 49.08
EV/Revenue3.24
10Y Low / Med / High3.03 / 4.00 / 5.53
P/FCF13.68
10Y Low / Med / High8.22 / 12.83 / 52.99

Intrinsic Value Models (per share)

DCF Value
$239.82
Graham Number
$34.15
Cash / Share
$6.16
MetricTrend2016201720182019202020212022202320242025TTM
P/E Ratio
21.89100.4617.1631.78-15.5919.7924.2313.22-12.8315.5913.75
P/S Ratio
5.034.853.764.193.292.993.322.362.372.282.54
P/B Ratio
6.048.596.052.123.703.854.933.617.025.965.42
EV/EBITDA
15.4916.9012.5719.6135.958.459.627.0349.089.6510.71
EV/Revenue
5.154.973.785.534.173.674.003.033.223.053.24

Analyst Estimates & Quality

Altman Z-Score
2.70
Grey Zone
Piotroski F-Score
7
Strong

Forward Estimates (consensus)

MetricFY2026FY2027FY2028
Revenue$50.11B$48.74B$40.64B
Net Income$13.21B$13.63B$10.89B
EPS$6.44$6.66$5.33
# Analysts (EPS)15168

Dividends

Dividend/Share (TTM)
$2.52
Dividend Yield
4.06%
Frequency
Quarterly

Recent Payments

Ex-DatePay DateAmountFrequency
Oct 2, 2026Nov 2, 2026$0.63Quarterly
Jul 2, 2026Aug 3, 2026$0.63Quarterly
Apr 2, 2026May 1, 2026$0.63Quarterly
Jan 2, 2026Feb 2, 2026$0.63Quarterly
Oct 3, 2025Nov 3, 2025$0.62Quarterly
Jul 3, 2025Aug 1, 2025$0.62Quarterly
Apr 4, 2025May 1, 2025$0.62Quarterly
Jan 3, 2025Feb 3, 2025$0.62Quarterly
Oct 4, 2024Nov 1, 2024$0.60Quarterly
Jul 5, 2024Aug 1, 2024$0.60Quarterly
Apr 4, 2024May 1, 2024$0.60Quarterly
Jan 4, 2024Feb 1, 2024$0.60Quarterly
Oct 5, 2023Nov 1, 2023$0.57Quarterly
Jul 6, 2023Aug 1, 2023$0.57Quarterly
Apr 6, 2023May 1, 2023$0.57Quarterly
Jan 5, 2023Feb 1, 2023$0.57Quarterly
Oct 6, 2022Nov 1, 2022$0.54Quarterly
Jun 30, 2022Aug 1, 2022$0.54Quarterly
Mar 31, 2022May 2, 2022$0.54Quarterly
Jan 6, 2022Feb 1, 2022$0.54Quarterly

Revenue Segments

By Product

Segment202020212022202320242025
Abraxane$1.25B$1.18B$811.0M$1.00B$875.0M$368.0M
Baraclude$447.0M—————
Eliquis$9.17B$10.76B$11.79B$12.21B$13.33B$14.44B
Empliciti$381.0M—————
Mature Products And All Other$1.31B$1.90B$1.75B———
Opdivo$6.99B$7.52B$8.25B$9.01B$9.30B$10.05B
Orencia$3.16B$3.31B$3.46B$3.60B$3.68B$3.71B
Pomalyst/Imnovid$3.07B$3.33B$3.50B$3.44B$3.54B$2.73B
Reblozyl$274.0M$551.0M$717.0M$1.01B$1.77B$2.33B
Revlimid$12.11B$12.82B$9.98B$6.10B$5.77B$2.95B
Sprycel$2.14B$2.12B$2.17B$1.93B$1.29B$493.0M
Yervoy$1.68B$2.03B$2.13B$2.24B$2.53B$2.90B
Zeposia$12.0M$134.0M$250.0M$434.0M$566.0M$577.0M
Abecma—$164.0M$388.0M$472.0M$406.0M$427.0M
Breyanzi—$87.0M$182.0M$364.0M$747.0M$1.36B
Camzyos——$24.0M$231.0M$602.0M$1.07B
Opdualag——$252.0M$627.0M$928.0M$1.19B
Sotyktu——$8.0M$170.0M$246.0M$291.0M
Cobenfy————$10.0M$155.0M
Krazati————$126.0M$205.0M
Other Growth Brands————$1.60B$1.92B
Other Legacy Brands————$925.0M$798.0M
Opdivo Ovantig—————$238.0M

By Geography

Segment202020212022202320242025
Europe$9.85B$10.69B$13.50B———
Other Region$631.0M$852.0M$834.0M$699.0M$996.0M$1.09B
Rest Of World$5.46B$5.63B—$12.75B$13.20B—
UNITED STATES$26.58B$29.21B$31.83B$31.55B$34.10B$33.28B